Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling

Alice Domenichini  
Curtin University

Ilaria Casari  
Curtin University

Peter V Simpson  
Curtin University

Nima Maheshkumar Desai  
Curtin University

Lingfeng Chen  
New York University

Christopher Dustin  
University of Vermont

Jeanne S Edmands  
Curtin University

Albert van der Vliet  
University of Vermont

Moosa Mohammadi  
New York University

Massimiliano Massi  
Curtin University

Marco Falasca (marco.falasca@curtin.edu.au)  
Curtin University  https://orcid.org/0000-0002-9801-7235

Research

Keywords: Rhenium complexes, pancreatic cancer, neuroblastoma, FGFR, Src

DOI: https://doi.org/10.21203/rs.3.rs-54828/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Platinum-based anticancer drugs have been at the frontline of cancer therapy for the last 40 years, and are used in more than half of all treatments for different cancer types. However, they are not universally effective, and patients often suffer severe side effects because of their lack of cellular selectivity. There is therefore a compelling need to investigate the anticancer activity of alternative metal complexes. Here we describe the potential anticancer activity of rhenium-based complexes with preclinical efficacy in different types of solid malignancies.

Methods: Kinase profile assay of rhenium complexes. Toxicology studies using zebrafish. Analysis of the growth of pancreatic cancer cell line-derived xenografts generated in zebrafish and in mice upon exposure to rhenium compounds.

Results: We describe rhenium complexes which block cancer proliferation in vitro by inhibiting the signalling cascade induced by FGFR and Src. Initially, we tested the toxicity of rhenium complexes in vivo using a zebrafish model and identified one compound that displays anticancer activity with low toxicity even in the high micromolar range. Notably, the rhenium complex has anticancer activity in very aggressive cancers such as pancreatic ductal adenocarcinoma and neuroblastoma. We demonstrate the potential efficacy of this complex via a significant reduction in cancer growth in mouse xenografts.

Conclusions: Our findings provide a basis for the development of rhenium-based chemotherapy agents with enhanced selectivity and limited side effects compared to standard platinum-based drugs.

Background

Cisplatin has been a frontline treatment for many cancers over the last 40 years (1, 2), and is still used for cancers of the bladder, ovary and testis, as well as for cancers of the head and neck. Although cisplatin has been successfully used in the treatment of many cancer types, the fact that it functions via random DNA targeting and induces harsh side effects, such as neurotoxicity and nephrotoxicity, makes it a far from ideal therapeutic agent (3). The development of chemoresistance is also a significant limiting factor in the use of this drug (2, 4). Carboplatin, another platinum-based drug that directly interferes with DNA metabolism, leads to the formation of cross-links in a manner similar to cisplatin. However, its more stable structure confers the benefit of having fewer side effects (5, 6), although its impact on bone marrow results in a reduction in blood cells including platelets (7). A further platinum-based drug with cytotoxic activity is oxaliplatin, which differs mechanistically from cisplatin and carboplatin as it promotes ribosome biogenesis stress leading to cell death (2). Because of the severe side effects that result from the use of all platinum-based drugs, other metal compounds are being studied for their anti-proliferative activity, with the goal of discovering new agents that are better tolerated by cancer patients.

Rhenium is a transition metal that has been recently studied for the development of novel anticancer agents (8-10). Its anticancer activity was first observed with tricarbonyl bismine complexes in HeLa cells (1, 4, 11-13). Several different complexes have been designed which utilize a combination of
organometallic ligands, such as N- or S-based ligands, oxo groups or peptides (14). Rhenium-containing compounds have been found to have promising anticancer activity associated with apoptosis (15), necrosis (16), autophagy (17), mitophagy (18) and oxidative stress (19). Notably, rhenium-based compounds have a great potential as theranostics (20). Indeed, rhenium possesses two isotopes, $^{186}$Re and $^{188}$Re, that have been used in nuclear medicine for more than fifty years (21). Rhenium use in medicinal pharmaceuticals, radio-imaging and luminescent probes has led to its consideration for use in diagnostic therapy. For example, Rhenium-188 hydroxyethylidenediphonate ($^{188}$Re-HEDP) is a drug that has been repurposed for the use in the treatment of prostate cancer with promising outcomes (22). In addition, when taxanes, known to increase the sensitivity of tumour cells to radiotherapy, and Rhenium compounds were combined for the treatment of prostate cancer, a significant additive anti-proliferative activity was observed (23). In spite of increasing evidence for their antiproliferative activity and the fact that different rhenium-based compounds have a much lower toxicity compared to other heavy metals, their mechanisms of action and structure activity relationships are not well understood, with only a few studies published to date (1, 9, 24).

Over the past few years, we have focused on the anticancer properties of rhenium tricarbonyl complexes bound to bidentate $N$-heterocyclic carbene ligands rather than di-imine ligands (Re-NHC) (10, 25). These compounds have demonstrated antiproliferative activity in pancreatic, neuroblastoma and ovarian cancer cells, while possessing low toxicity. Here we present an investigation of the mechanism of action of Re-NHC complexes and the results of experiments to test their activity in vivo.

**Methods**

**Cell Culture**

Human pancreatic cancer and neuroblastoma cell lines were obtained from the American Type Culture Collection (ATCC) and cultured as per ATCC® guidelines. AsPC-1 (ATCC® CRL-1682™) and BxPC3 (ATCC® CRL-1687™) required RPMI-1640 as base medium, with the addition of foetal bovine serum (FBS) to a final concentration of 10% and glutamine to a final concentration of 2mM. HPAF-II (ATCC® CRL-1997™) cells were cultured in Eagle’s Minimum Essential Medium (EMEM) medium with the addition of FBS to a final concentration of 10% and glutamine to a final concentration of 2mM. SW1990 (ATCC® CRL-2172™) were cultured in Leibovitz’s L-15 Medium, with the addition of FBS to a final concentration of 10%. SH-SY5Y (ATCC® CRL-2266™) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 1% penicillin/streptomycin, 2 mM glutamine and 10 mM sodium pyruvate. IMR-32 (ATCC® CCL-127™) cells were cultured in RPMI-1640 medium containing 10% FBS, 2 mM glutamine supplemented, 10 mM sodium pyruvate and 10 mM non-essential amino acids (NEAA).

Pancreatic cancer tumorspheres enriched in cancer stem cells were cultured according to the protocol previously described by Domenichini et al. (26). Primary mouse pancreatic cancer cells KPC were used according to the protocol previously described (26). The KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg+/+) mouse model is a clinically relevant genetically engineered mouse model (GEMM) for PDAC.
Mutationally activated Kras and mutated p53 drive the development of a pancreatic intraepithelial neoplasia that eventually progresses into pancreatic ductal adenocarcinoma with pathological features closely resembling the human disease (27). LAN-1, KELLY and the primary human neuroblastoma cell line (hNB) were provided by Professor Arturo Sala (Brunel University) and cultured as described (28).

**Western Blots**

Cell lysates and tissues were homogenised in RIPA buffer (50 mM TRIS-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 5mM EDTA) supplemented with a protease and phosphatase inhibitor cocktail (Roche). To terminate the reaction, SDS sample buffer [125 mM Tris- HCl (pH 6.8), 6% SDS, 20% glycerol, and 0.02% bromophenol blue supplemented with 10% β-mercaptoethanol] was added and the samples boiled for 10 min. Proteins were separated on SDS-PAGE 8 to 12% Tris-glycine gels (Life Technologies) and transferred to a nitrocellulose membrane (BioRad). For protein detection, membranes were incubated in 3% BSA in TBS/0.05% Tween-20 blocking buffer for 1 h at room temperature, and incubated overnight at 4 °C with primary antibodies from Cell Signaling Technology®: Phospho-FGFR(Y653/654) (#3471), Phospho-Src Family(Y416) (#2101), N-Myc (#9405), Phospho-Akt(T308) (#9275) and GAPDH (#5174), the latter used as a loading control. The following day, membranes were incubated with HRP-conjugated secondary antibodies (Cell Signaling Technologies) at a 1:40000 dilution in 0.75% BSA in TBS/0.05% Tween-20 buffer for 1 h at room temperature. Signal was detected using the chemiluminescent detection reagent Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences) and imaged using BioRad ChemiDoc XRS+.

**Soft Agar Colony Formation**

The anchorage independent soft agar colony formation assay is a well-established protocol to measure the proliferative capacity of cancer cells (29). Media were prepared as 2X concentrated solutions, including noble agar (Sigma-Aldrich) as two stocks to be diluted 2X media solutions, 1.2% for the first layer and 1% for the second layer (the cell layer). Six well plates were coated with a first layer (2 mL) of 1.2% noble agar in 2X RPMI (final 0.6% agar in 1X media). Cells were counted using trypan blue exclusion and about 3x10^4 cells were resuspended in 5 mL of 0.5% noble agar (1% noble agar in 2X media) prior to treatment. For each six well plate, the first row (3 wells) was seeded with cells treated with JVG045 (10mM) and the second row with cells treated with DMSO. Once the first layer had settled, 1.5 mL of cell suspension containing approximately 1x10^4 cells in 0.5% noble agar was distributed on top of the first layer. The top layer was then covered with complete RPMI and the plates incubated at 37°C in a 5% CO₂ incubator for 4 weeks. Media were removed and colonies fixed for 10 minutes at room temperature with 10% Methanol/10% glacial acetic acid. Colonies were stained with 0.05% crystal violet solution (Sigma-Aldrich) for 30 minutes at room temperature on a rocking shaker and subsequently washed with water on a rocking shaker to clear the agar. Colonies were imaged using BioRad ChemiDoc XRS+ and counted using ImageJ.

**Kinase Profiler**
A screen was done to determine the effect of JVG045 and Ps27 on the activity of a panel of protein-kinases via SelectScreen Kinase Profiling Service (Invitrogen-Life Technologies, Paisley, UK). The assay used 1μM of various compounds and ATP at the concentration noted (see Supplementary Tables).

**Analysis of effects of JVG045 on tyrosine trans-phosphorylation activity of FGFR1\textsuperscript{Cys488} kinase**

N-terminally His-tagged FGFR\textsuperscript{1Cys488} kinase carrying a native cysteine at position 488 in the glycine-rich loop was expressed in BL21 (DE3) E. coli cells at 20°C overnight. Cells were lysed in 25 mM HEPES pH 7.5 buffer containing 150 mM NaCl and 10% glycerol. Cell lysis and subsequent column chromatography purifications were done in presence reducing agent (i.e., 10 mM \(-\text{mercaptoethanol} or 2 \text{ mM DTT}) to avoid Cys488-mediated disulfide-linked dimerization of kinases. Following high speed centrifugation at 20,000 x g, supernatant was filtered, and loaded onto Ni\textsuperscript{2+} metal affinity chromatography column (5 mL) (GE Healthcare Life Sciences). Bound FGFR\textsuperscript{1Cys488} kinase was eluted with 18 column volumes of linear gradient of 0.5 M imidazole, and applied onto a SourceQ anion exchange chromatography column (20 mL) (GE Healthcare Life Sciences). Column was developed with 13 column volumes of linear gradient of 1 M NaCl. Fractions containing FGFR\textsuperscript{1Cys488} kinase were pooled, concentrated, and applied to a Superdex 75 column (GE Healthcare). Eluents containing kinase protein were then pooled, concentrated and incubated overnight with FastAP\textsuperscript{TM} Thermosensitive Alkaline Phosphatase (#EF0651; Thermo Scientific), and re-purified by Source Q column chromatography as above to obtain highly homogenous phosphorylation-free FGFR\textsuperscript{1Cys488} kinase.

Purified FGFR\textsuperscript{1Cys488} kinase was incubated with or without compound JVG045 (100 μM) overnight at 4 °C. Trans-phosphorylation on tyrosines was initiated by mixing FGFR\textsuperscript{1Cys488} kinase with a reaction buffer containing ATP and Mg\textsubscript{Cl2} to final concentrations of 67.5 μM (kinase), 25 mM (ATP) and 50 mM Mg\textsubscript{Cl2}. Reactions were quenched at different times (as indicated in figure) by adding EDTA (final concentration, 50 mM) to the reaction mixture. The progress of FGFR kinase trans-phosphorylation was monitored by native-PAGE (#17062401, GE Healthcare).

**Src Kinase assay**

Recombinant Src were expressed in BL21-AI *Escherichia coli* (Thermo) containing the pEX-Src-C-His (Origene, Blue Heron Biotech) and purified in a modified procedure as previously described (30). The Src kinase assay used was the ADP-GLO assay (Promega) according to manufacturer protocol. Specifically, the kinase (1 ng) was incubated with between 10 nm-10 mM JVG045 compound/AZD0530 in 15 μL of kinase buffer for 30 min prior to the addition of 10 μL substrate solution containing ATP and poly[4Glu:Tyr] (Sigma). This reaction was allowed to react at RT for 1 hour prior to quenching with ADP-Glo reagent for 40 min, followed by the addition of ADP-GLO detection reagent for 30 min prior to reading luminescence on a 96-well microplate reader.

**Animal Experiments**
**Toxicology studies**

24 hours post fertilisation (hpf) zebrafish embryos were equally distributed into wells of a 24-well plate (about 10 embryos/well) and treated with increasing concentration of selected compounds as shown in Supplementary figure 2. Compounds were prepared in DMSO and then diluted to the final concentration in embryo medium (E2), which is a physiological solution (31).

Embryos were observed daily at 24 hours intervals and toxicity scores (hatching and mortality) were recorded until 120hpf. For heart rate assessments, embryos were anesthetized with tricaine (ethyl 3-aminobenzoate methanesulfonate) at 48hpf and counted under the stereomicroscope for 1 min. To assess JVG045 teratogenicity compared to BGJ398, embryos were treated with the compounds starting from 2hpf and results observed at 24hpf. Compounds were prepared in DMSO and diluted to the final concentration in E2 embryo medium > DMSO was used as negative control.

**Zebrafish Xenografts**

For zebrafish xenografts, wild type Tübingen (TU) zebrafish were bred and maintained in the Western Australian Zebrafish Experimental Research Centre (Biomedical Research Facility- Shenton Park, Western Australia). Experiments and data analyses were done as previously described (32). Briefly, HPAF-II human pancreatic cancer cells were incubated with Vibrant™-Dil dye (ThermoFisher Scientific) 4 μL/mL in HBSS at 37°C for 10 minutes, followed by 15 minutes on ice in the dark. Cells were then harvested and resuspended at a density of 10⁷ cells/, loaded into a capillary glass needle using a puller (p-97 Flaming/Brown by Sutter Instrument®) and 10nL of cell suspension (approximately 100 cells/embryo) was injected in the perivitelline space of 24-hour post fertilisation (hpf) zebrafish embryos. Zebrafish were incubated at 34°C O/N to allow for cell growth and the following day embryos were equally distributed in to three treatment groups. One group did not receive any treatment (blank), a second group was treated received 0.1% DMSO and a third group was treated with 10µM JVG045. At 5 days post fertilisation (dpf), the effect of the drugs on cancer cell growth was documented using a fluorescent stereomicroscope equipped with a digital camera (Nikon SMZ Zoom). Images were analysed using ImageJ. Non injected embryos were used to subtract background fluorescence.

**Mice Xenografts**

Six to seven-week-old NOD/SCID (NOD.CB17-Prkdcscid/Arc) immune-deficient mice were purchased from the Animal Resources Centre (ARC-Murdoch-Western Australia) and maintained under pathogen-free conditions with water and food provided ad libitum. Mice were injected subcutaneously randomly on either the left or the right flank with 3.5 × 10⁶ HPAF-II human pancreatic cancer cells following a previously described protocol (32). When tumours reached a volume of about 50 mm³ (according to the formula: tumour volume = 1/2(length × width²), mice were randomized into two groups and treated with either vehicle (0.5% carboxymethyl cellulose (CMC)/0.4% Tween-80) or JVG045 30mg/kg as a daily intra-peritoneal injection (IP) in a volume of 250mL. Animal health conditions were monitored daily and
tumours were measured three times a week by an unbiased operator until the largest tumours reached a volume of 1500mm$^3$. Procedures involving animals and their care were established according to the institutional guidelines in compliance with national and international policies (Curtin Animal Ethics Committee Approval 2016-40).

**Reactive Oxygen Species (ROS) Measurement by Flow Cytometry**

The increase in production of reactive oxygen species (ROS) was measured using the oxidation of 2'-'7' dichlorofluorescin diacetate (H2DCF-DA Sigma Aldrich D6883). Cells were seeded in a 6-well plate at a density on 3.5x10$^5$ cells/well and incubated overnight. The following day, cells were treated with either DMSO or JVG045 (10mM) for one hour. Antimycin (50mM) was used as positive control. Cells were then washed with PBS and loaded with 1mg/mL of H2DCF-DA diluted in serum-free medium for one hour while protected from light. After incubation, cells were detached, washed twice with ice-cold PBS and resuspended in PBS containing 1mg/mL propidium iodide to exclude dead cells. Corresponding unstained controls were also prepared. Cells were analysed using a BD FACSCantoTMII flow cytometer and data were analysed using FlowJo® software.

**Physiochemical and metabolic parameters**

Physiochemical and metabolic parameters studies have been performed at the Centre for Drug Candidate Optimisation, Monash University, as described below.

1. **a) Calculated physicochemical parameters using ChemAxon JChem software**

A range of physicochemical properties were calculated using the Chem Axon chemistry cartridge via JChem for Excel software (version16.4.11).

b) **Kinetic Solubility Estimation using Nephelometry (SolpH)**

Compound in DMSO was spiked into either pH6.5 phosphate buffer or 0.01M HCl (approx pH2.0) with the final DMSO concentration being 1%. After 30 minutes had elapsed, samples were then analysed via Nephelometry to determine a solubility range (33).

c) **Distribution Coefficient Estimation using Chromatography (gLogDpH)**

Partition coefficient values (LogD) of the test compounds were estimated at pH7.4 by correlation of their chromatographic retention properties against the characteristics of a series of standard compounds with known partition coefficient t values. The method employed is a gradient HPLC based derivation of the method developed by Lombardo et al. (34).

**In Vitro Metabolic Stability**

The metabolic stability assay was performed by incubating the compound (0.5 μM) in liver microsomes at 37°C and a protein concentration of 0.4mg/mL. The metabolic reaction was initiated by the addition of an NADPH-regenerating system and quenched at various timepoints over a 60-minute incubation period by the addition of acetonitrile containing diazepam as internal standard. Control samples (containing no NADPH) were included (and quenched at 2, 30 and 60 minutes) to monitor for potential degradation in the absence of cofactor. The human liver microsomes used in this experiment were supplied by XenoTech, lot#1410230. The mouse liver microsomes used in this experiment were supplied by XenoTech, lot#1510256.
Statistical Analyses

The results presented are representative of at least three independent experiments. Statistical analyses were done using GraphPad Prism v.8.4.2, and normalisation of data was applied where appropriate. Statistical significance was considered at a value of p < 0.05.

Results

Re-NHC complexes with inhibitory activity towards FGFR1 and Src

We recently showed that Re-NHC complexes suppress the growth of pancreatic cancer cell lines by blocking the cells in the G2/M phase via a mechanism involving the inhibition of phosphorylation of aurora kinase A (35). We have now identified a subset of compounds as good candidates for further studies and for possible therapeutic drug development. Two of these compounds, JVG045 and ps27 (see structures in Supplementary Figure 1) showed good pharmaco-toxicological profiles and were selected for activity analysis in more detail (see below and Supplementary Figure 2).

To gain insight into their mechanism of action, we did a large unbiased cell-free assay involving a protein kinase screen using these compounds (SelectScreen Kinase Profiling Service, Invitrogen-Life Technologies). This screen involves a single point inhibition assay at 1 μM against more than 120 kinases (Supplementary Table 1). Compounds JVG045 and ps27 showed >50% inhibitory activity towards Fibroblast Growth Factor Receptor (FGFR1) and Src (Fig. 1A) and did not inhibit (percentage of inhibition <40%) any of the other kinases tested. Further evidence for this inhibition was obtained by Western blot analyses (Fig. 1B), which were used to compare the levels of phosphorylated Fibroblast Growth Factor Receptor (pFGFR) in two different pancreatic cancer cell lines (HPAF-II and AsPC-1) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to normalise protein content. The level of pFGFR1 Tyr653/654 was analysed under normal conditions (i.e., DMSO control) and after incubation with JVG045 at 10 mM. We focussed on JVG045 rather than ps27 because of the latter's toxicity, as explained further below. The effect of JVG045 was also compared with an equal amount of a known specific FGFR inhibitor, BGJ398, as a positive control; the inert [Re(CO)3(phen)Cl] (where phen is 1,10-phenanthroline; the complex is referred herein to as ReCl) compound was used as a negative control (Supplementary Figure 1). The results clearly show that JVG045 reduces the levels of phosphorylation of FGFR with an effect comparable to BGJ398. Furthermore, we assessed the effect of JVG045 on FGF-induced downstream signalling and we found that JVG045 strongly attenuated FGF-induced Akt phosphorylation at Thr308 in both AsPC-1 and HPAF-II (Supplementary Figure 3).

Surprisingly, assessment of the substrate phosphorylation activity of purified FGFR1 showed no difference in kinase activity in the presence of 10mM JVG045 (Fig. 1C). Furthermore, a direct kinase assay for Src using JVG045 at various concentrations showed no difference in protein activity compared to the specific Src inhibitor Saracatinib (AZD0530, Fig. 1D). These results indicate that the inhibitory activity of JVG045 on FGFR1 and Src kinases is indirect, either as a kinase inhibitor or as a covalent inhibitor (36). In addition, JVG045 was more efficient than ps27 in inhibiting the phosphorylation of FGFR
in pancreatic cancer cell lines ASPC-1 (see Supplementary Figure 4A) and HPAF-II (Supplementary Figure 4B). We therefore set out to determine the mechanism of action of JVG045 on the phosphorylation of FGFR1 and Src.

It has been shown that both FGFR1 and Src can be inactivated by a mechanism involving the direct oxidation of a specific cysteine residue (Cys-277 in Src and Cys-488 in FGFR1) (37). Furthermore, it has been suggested that tricarbonyl rhenium complexes exert anticancer activity by elevating intracellular levels of reactive oxygen species (ROS) (17). Therefore, we determined the ability of JVG045 to induce the production of intracellular ROS. Our results show that, at a concentration of 10mM, JVG induces a significant increase in ROS production in human pancreatic cancer cell lines AsPC-1 (p=0.0286; Fig. 1E) and HPAF-II (p=0.0022; Fig. 1F). We conclude that JVG045 inhibits FGFR1 and Src indirectly, possibly through oxidation of cysteine residues.

**Toxicology studies in zebrafish**

With the intent to test compounds on mouse models *in vivo*, we first verified their toxicity using zebrafish as a screening platform. Six compounds were selected based on previous *in vitro* results and compared to 1% DMSO (as a control) and Cisplatin, in a dose response experiment done by dissolving the drugs in zebrafish embryo medium in 24-well plates. Compounds JVG080, ps139a and ps197c formed crystals in the embryo medium (a physiological solution), and were therefore discarded from further investigation as unpromising drug candidates because of their limited solubility (Supplementary Figure 2). We therefore proceeded with toxicity studies on zebrafish embryos in which we compared the toxic effect of JVG045 and ps27 to cisplatin. DMSO was used as negative control. Hatching and mortality rate are widely accepted parameters for the evaluation of substance toxicity using the zebrafish model (38). Zebrafish embryos normally hatch around three days post fertilisation; our data show that when DMSO (Fig. 2A) was included in the embryo medium, at increasing concentration, 97.3% (±3.7 SD) of the embryos hatched after 3 days (72 hours post fertilisation, hpf) and 99.6% (±0.9 SD) of the larvae were free from their chorion at 5 days (120hpf). On the other hand, with cisplatin, even at the lowest concentration (50µM) only 15% (±12.9 SD) of the embryos hatched at 72hpf, increasing to an average of 27.5% (±30.9 SD) at 120hpf (Fig. 2B). In comparison with JVG045 at a concentration 10 times higher (500µM), 50% (±46.9 SD) of the embryos hatched at 72hpf, increasing to an average of 78 (±30.3 SD) at 120hpf (Fig. 2C). In contrast, ps27 showed toxicity starting at a concentration of 100µM, when only 6.7% (±11.5 SD) of embryos hatched after 72hpf, with an average of 33.3% (±49.3 SD) of hatched larvae after 120hpf (Fig. 2D). Mortality rate was assessed daily until 120hpf (5 days); mortality in the presence of 1% DMSO, which was null (Fig. 2E), was considered as the reference control. In the presence of cisplatin, 47.5% (±17.1 SD) of larvae died by 120hpf at 50µM and the mortality rate reached 100% at a concentration of 500µM, with 25% (±50.0 SD) of embryos already dying at 55hpf (Fig. 2F). However, when zebrafish embryos were exposed to JVG045 at the highest concentration (500µM), mortality was null at 55hpf and reached 60% (±39.4 SD) at 120hpf (Fig. 2G). In comparison, when the embryos were exposed to ps27, the mortality rate at 120hpf was 63.3% (±46.2 SD) at a concentration five times lower than JVG045 (100µM).
and reached 96.7% (±5.8 SD) at 150µM (Fig. 2H). We conclude that JVG045 has the lowest toxicity index and consequently offers significant potential as a drug candidate.

Given these encouraging data, we investigated additional toxicity parameters on zebrafish embryos by monitoring the effects of increasing concentrations of JVG045 and corresponding percentages of DMSO on heartbeat. The normal zebrafish embryonic heartbeat rate is 140-180 beats per minute (bpm); this parameter is an established criterion for the evaluation of substance toxicity (39). Our analyses showed that heartbeat rates did not differ from data reported in the literature across all concentrations (DMSO average 142.0 bpm ± 11.17 SD; JVG045 average 138.4 bpm ± 12.95). In addition, across all concentrations, there was no significant difference in the heartbeat rate between embryos exposed to either control or JVG045 (Paired t-test t(5) =0.5706, p=0.5930; Fig 2I).

We took advantage of zebrafish transparency and rapid development, which allow easy detection of developmental defects in the main organs and structures (40), to examine the effects of JVG045 on embryogenesis. BGJ398 is a fibroblast growth factor receptor (FGFR 1-3) inhibitor (41), and when tested in zebrafish at a concentration of 0.5-1mM, it impairs the proper development of the embryo in the posterior mesoderm and tail morphogenesis (36). We found that JVG045 did not show any zebrafish embryonic teratogenicity, consistent with the notion that the mechanism of action of JVG045 is indirect (Fig 2J). In addition, in zebrafish fgfr genes display functional redundancy, and thus inhibition of the activity of only one of these genes activates a compensatory activity from the other gene (42) such that development proceeds normally.

**JVG045 inhibits KPC mouse-derived primary cancer cell growth and reduces their anchorage-independent growth.**

To better understand the potential efficacy of the selected Rhenium compound in a tumour setting, we tested the effect of JVG045 on primary cell cultures derived from pancreatic ductal adenocarcinoma isolated from KrasLSL.G12D/+; p53R172H/+; PdxCre/+ (or KPC) mice. We found that JVG045 impairs KPC primary cell growth in a dose-dependent manner (Fig 3A,B), reaching statistical significance at 5 and 10µM (One-way ANOVA F(4,20) =11.87, p<0.0001). We also tested the effect of 10mM JVG045 on anchorage independent soft agar colony formation, which measures the ability of cancer cells to grow and to proliferate without support on a solid surface (29, 43). Our data showed that at this concentration, JVG045 significantly impaired the anchorage-independent growth of KPC primary cell colonies in soft agar (two-sample t-test, t(6) = 5.544; p= 0.0015; Fig. 3C, D).

**Re-NHC complexes show anticancer activity in neuroblastoma cell lines with an amplified MYCN oncogene**

To determine the efficacy of JVG045 on different cell types, we screened a variety of cell lines derived from different cancer types (Table 1). These experiments showed that this compound is particularly active in inhibiting *in vitro* growth of human neuroblastoma cell lines containing an amplification of the *MYCN* proto-oncogene (Kelly, IMR32, LAN1), while having only a limited effect on neuroblastoma cell
lines lacking MYCN amplification (Fig. 4A) (44). For example, treatment with JVG045 at up to 20mM in the MYCN-non-amplified cell line SHSY5 had no significant effect on cell number (One-way ANOVA, $F_{(5,9)}=1.157, p=0.3989$). Similarly, in the MYCN-non-amplified primary human neuroblastoma cell line hNB, treatment with JVG045 up to 20mM had no significant effect ($F_{(5,9)}=1.649, p=0.2421$). In contrast, in the MYCN-amplified cell lines Kelly ($F_{(5,12)}=51.56, p<0.0001$) and IMR32 ($F_{(5,12)}=21.37, p<0.0001$), the effect of JVG045 treatment on cell number reduction was significant starting at 2.5mM ($p=0.0084$ in Kelly and $p=0.0212$ in IMR32). JVG045 also significantly ablated cell number in another MYCN-amplified cell line, LAN1 (One-way ANOVA, $F_{(5,12)}=36.06, p<0.0001$) starting at a concentration of 5mM ($p=0.0192$). Figure 4B shows a representative Western Blot analysis showing the Kelly human neuroblastoma cell lines treated with JVG045, together with the FGFR inhibitor BGJ398 and the Src kinase inhibitor Bosutinib. Data from the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) databases confirm that FGFR1 (Fig. 4C, D) and Src (Fig 4E, F) are unfavourable prognostic markers for pancreatic cancer adenocarcinoma and human neuroblastoma.

Oncogene KRAS status determines responsiveness to JVG045 in pancreatic cancer cell lines.

To test the effect of JVG045 on pancreatic cancer cells with varying degrees of genetic complexity (ATCC® TCP-1026), we exposed a range of cell lines to JVG045. These experiments showed that, compared to K-RAS mutated cell lines (IC50 AsPC1 4.0±1.2mM, HPAF-II 5.6±0.6mM, CFPAC 5.7±2.8mM (25) and Supplementary Table 2), JVG045 had an insignificant effect on the only cell line that contains wild-type RAS and is not RAS-activated, BxPC-3 (IC50 >20mM; One-way ANOVA, $F_{(5,17)}=0.6535, p=0.6630$; Fig 5A). In contrast, SW1990, a pancreatic cancer cell line with mutationally activated KRAS but bearing wild type tumour suppressor P53, displayed a statistically significant dose-dependent reduction of cell number in response to JVG045 treatment (IC50 = 5.4mM; One-way ANOVA, $F_{(5,12)}=8.208, p=0.0014$; Fig 5A). Western blot analysis on BxPC-3, when probed for pFGFR and pSrc, showed no difference following JVG045 treatment (10 mM) compared to an untreated control in presence or absence of FGF ligand (Fig 5B). We next determined the effect of JVG045 on cell growth in K-RAS mutated non-pancreatic cancer cell lines. We found that JVG045 is able to inhibit both K-RAS mutated ovarian (OVCAR5) and lung cancer cell lines (A549) in a dose-dependent manner (Supplementary Figure 5 and Supplementary Table 2).

We also verified the efficacy of JVG045 in a population of pancreatic cancer tumorspheres enriched in cancer stem-like cells (26). Cancer stem-like cells are slow-cycling cells with a capacity for self-renewal that can elude most therapeutic treatments and are thus responsible for chemoresistance, tumour relapse and metastatic spread to distant sites (45). We previously showed that pancreatic cancer tumorspheres are highly resistant to the main therapeutic drugs Gemcitabine and Carboplatin (26). To test its potential as a therapeutic agent, we tested JVG045 on tumorspheres isolated from the human pancreatic cancer cell line AsPC-1. These experiments showed that JVG045 at 10mM significantly reduced the number of cancer stem-like cells in AsPC-1 (two-sample t-test, $t_{(6)}=9.429; p<0.0001$; Fig. 5C). In contrast, when tested on tumorspheres isolated from the KRAS wild type pancreatic cancer cell line BxPC-3, no significant effect of JVG45 was observed (two-sample t-test, $t_{(4)}=1.224; p=0.2880$; Fig. 5D). Importantly, primary KPC
tumorspheres enriched in cancer stem cells and isolated from primary pancreatic ductal adenocarcinomas in KPC mice showed a significant reduction in cell number after treatment with 10mM JVG045 (two-sample t-test, \( t_{(4)} = 4.158; p=0.0142 \); Fig. 5E).

**JVG045 reduces in vivo PDAC progression in xenografts models.**

We next tested the antitumor activity of JVG045 *in vivo* using different xenografts models. Following a previously described protocol (32), we injected 100-200 Dil-labelled (Vybrant™ DiI Cell-Labeling Solution, ThermoFisher Scientific) HPAF-II human pancreatic cancer cells into the perivitelline space of 24 hour-old zebrafish embryos. After 24 hours, embryos were treated with either DMSO or 10μM JVG045 for 3 days, until the embryos reached 5 days post fertilisation (Fig. 6A). At the end of the experiment, 15/25 embryos DMSO-treated were alive, while all zebrafish treated with JVG045 survived till the end of the experiment (21/21). Moreover, treatment with the tricarbonyl rhenium compound significantly reduced the overall tumour burden (two-sample t-test, \( t_{(16)} = 2.887; p=0.0107 \); Fig. 6B).

To extend these data to a mammalian context, we examined the therapeutic effect of JVG045 on mice harbouring HPAF-II human pancreatic cancer cell line xenografts. These mice were treated with a daily intra-peritoneal injection of JVG045 (30mg/kg) over a 25-day period; the experiment was terminated when the tumours reached the critical limit volume of 1500mm\(^3\). Body weight and tumour measurements were recorded to assess whether JVG045 was well tolerated. Data from multiple t-tests for different measurement points showed no significant difference between the weight of xenograft-bearing mice treated with vehicle, compare to those treated with JVG045 (Supplementary Figure 6). Notably, however, JVG045 was effective in reducing the tumour burden, with a small but significant effect in reducing the tumour volume after 23 days of treatment (mean Vehicle = 1,262.483mm\(^3\) ± 328.433, n=8; mean JVG045 = 1,010.422mm\(^3\) ± 275.295, n=9; t ratio\(_{(158)}\) = 2.481; \( p=0.0141 \)) and after 25 days of treatment (mean Vehicle = 1,702.1mm\(^3\) ± 588.412, n=8; mean JVG045 = 1,468.022mm\(^3\) ± 364.188, n=9; t ratio\(_{(158)}\) = 2.499; \( p=0.0136 \)) (Fig 6C, D). However, no significant difference was found in the weight of the tumours at the end of the experiment (mean Vehicle = 821mg ± 187.1, n=8; mean JVG045 = 733.6mg ± 189.5, n=9; t\(_{(15)}\) = 0.9580; \( p=0.3533 \); Fig. 6E).

To establish whether there was any effect of JVG045 on the phosphorylation of Src at tyrosine residue 416 and/or FGFR or at tyrosine residues 653/654, we prepared extracts from a section of the tumours and performed western blot analyses (Fig. 7A). Quantification of the WB signal was normalised to the loading control and the average data for untreated (control) tumour-bearing mice was compared to the average for tumour-bearing mice treated with JGV045. On average, we observed a significant inhibition of phosphorylation of Src at Tyr416 (Fig. 7B) in animals harbouring tumours treated with JVG045 compared to control (vehicle) treated tumours (two-samples t-test on normalised data \( t_{(14,97)} = 2.207, p=0.0434 \)). However, no significant difference was detected on the levels of Tyr653/654 phosphorylation of FGFR (two-samples t-test on \( t_{(15)} = 0.04187, p=0.9672 \); Fig. 7C).

**Physiochemical and metabolic evaluation of JVG045**
Finally, we assessed JVG045 for its physiochemical (Table 2A) and metabolic properties (Table 2B), including kinetic solubility, chromatographic LogD (gLogD) and microsomal stability in human and mouse liver microsomes. JVG045 exhibited poor solubility in pH6.5 buffer, which remained unchanged in a pH2 buffer, inferring neutral character. The lipophilic butyl chain is a likely contributor towards the poor solubility of this compound. JVG045 exhibited moderate lipophilicity (Table 2A). Metabolic stability was assessed at a substrate concentration of 0.5μM in human and mouse liver microsomes. JVG045 showed a moderate rate of NADPH-dependent degradation in both human and mouse liver microsomes, with no indication of non-NADPH dependent metabolism in microsomal control samples.

Discussion

Despite the extensive clinical utilization of platinum-based drugs as anticancer agents over more than four decades, their use is currently limited by the occurrence of severe adverse events and the development of chemoresistance. Attempts to substitute platinum with other metals has not produced tangible results in a clinical setting. Among all metal-based drugs, those containing rhenium have recently attracted major interest: several rhenium-based compounds have been tested for their anticancer activity *in vitro* and *in vivo* with promising results (24, 46-49). However, the lack of a known mechanism of action and molecular target represents a major obstacle in advancing these therapeutics to the clinical trial stage. In previous work, we identified Re-NHC complexes that can induce G2/M arrest and inhibition of the aurora kinase A phosphorylation (25). Here, we characterized the molecular targets of our leading compounds and evaluated their anticancer potential *in vitro* and *in vivo*. Based on the data we present, we surmise that our rhenium-based compounds target FGFR and Src, possibly through ROS interaction with specific cysteine residues. How exactly the rhenium compounds inhibit FGFR1 and Src remains to be determined. It is currently unclear why our compounds showed inhibitory effects in the kinases screen but not in the individual kinase activity or autophosphorylation assay. A possible explanation is the presence of different amounts of redox reagents such as dithiothreitol. Our proposed ROS-based mechanism is consistent with previous work showing that both FRGFR and Src are regulated by ROS-mediated cysteine oxidation (37). On the other hand, our previous work suggested that low levels of ROS can enhance Src activation, and therefore, JVG045 by targeting the conserved cysteine residue could prevent such oxidative activation (30). Another aspect that needs to be determined is the lack of embryonic teratogenicity of JVG045 compared to the pan-FGFR kinase inhibitor BGJ398. Zebrafish embryo development is dependent on FGFRs and the four FGFRs present in zebrafish are highly redundant and it is possible that JVG045 is not able to block all zebrafish FGFRs (42). Alternatively, a possible explanation could be that the targeted cysteine is not present in the zebrafish FGFR. Indeed, a comparison of the human FGFRs sequences shows that in the zebrafish counterpart few cysteine residues are missing (50-52). Interestingly, recent data demonstrated that aurora kinase A is also regulated by reversible cysteine oxidation suggesting that our observed Aurora Kinase inhibition by JVG045 could occur through a similar proposed mechanism (53). Our results showed that JVG045 is rather specific in targeting K-Ras mutated pancreatic cancer cells and MYCN amplified neuroblastoma cells. The toxicity profile of our lead compound in zebrafish and mouse is also very favourable. The anticancer activity of our lead compound
was also investigated using zebrafish and mice models. Our results showed that JVG045 is able to inhibit tumour growth in vivo, although the activity in mice was less impressive compared to the zebrafish model. This is likely due to solubility issue as shown by our physiochemical studies. Furthermore, we could confirm in vivo inhibition of Src phosphorylation but not FGFR1. This indicates that JVG045 is able to reach the tumour but probably the concentration and/or the duration of persistence in the circulation is suboptimal. Although our study provides strong evidence of in vivo activity for rhenium tricarbonyl compounds, it is clear that the pharmacodynamics and pharmacokinetics of these compounds require improvement. Moreover, it would be interesting to see whether multiple administrations (i.e. twice a day) or higher concentrations are able to increase the anti-tumour activity in mouse models.

Conclusions

In conclusion, this work provides novel mechanistic insight and the molecular targets for Re-NHC complexes and demonstrates their specificity in blocking cancer growth in vitro and in vivo. The minimal or lack of activity of these compounds in non-malignant cells and in cancer cells with wild type KRas and low levels of MYCN is a promising feature for the development of novel therapies. The identification of the mechanism of action and of the molecular targets is pivotal for the advancement of these agents in an effort to develop efficacious and non-toxic therapeutics. Both FGFR1 and Src play a key role in cancer progression and it is therefore anticipated that the development of these novel anticancer agents could have a broad spectrum of application in different cancer settings.

Declarations

Funding: This project is made possible by an Avner Pancreatic Cancer Foundation grant (http://www.avnersfoundation.org.au).

Author Contributions: A.D.: conceptualization, investigation, data curation, formal analysis, methodology, writing original draft, writing review and editing. I.C.: investigation, data curation, formal analysis, methodology, writing original draft, writing review and editing. P.V.S.: compounds design and synthesis, methodology, writing review and editing. N.M.D.: investigation, data curation, methodology. L.C.: FGFR assay, methodology, data curation. C.D: Src assay, methodology, data curation. J.S.E.: FACS analysis, data curation, methodology. A.V.: Src assay, methodology, data curation, visualization, resources, supervision, writing review and editing. M.M.: FGFR assay, methodology, data curation, visualization, resources, supervision, writing review and editing. M.M.: compounds design and synthesis, methodology, writing review and editing. M.F.: conceptualization, investigation, data curation, formal analysis, methodology, writing original draft, writing review and editing, project administration, funding acquisition, supervision.

Conflict of interest disclosure statement: All authors declare they have no competing interests.
Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate: This study has been conducted in accordance with ethical standards and according to the Declaration of Helsinki and the national and international guidelines, and has been approved by the authors’ institutional review board. The Curtin University Animal Ethics Committee approved procedures on xwnograft (AEC_2016_40).

Consent for publication: Not applicable.

Acknowledgements

The authors acknowledge the infrastructure and staff support provided by CHIRI, School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University and the Western Australian Zebrafish Experimental Research Centre. The authors would also like acknowledge the support of the Keith & Ann Vaughan Pancreatic Cancer Fund. We thank Prof Arturo Sala for valuable discussions and comments.

Abbreviations

Fibroblast Growth Factor Receptor (FGFR); glyceraldehyde-3-phosphate dehydrogenase (GAPDH); KrasLSL.G12D/+; p53R172H/+; PdxCre/+ (KPC); Rhenium N-heterocyclic carbene (Re-NHC); reactive oxygen species (ROS).

References

1. Leonidova A, Gasser G. Underestimated potential of organometallic rhenium complexes as anticancer agents. ACS chemical biology. 2014;9(10):2180-93.
2. Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature medicine. 2017;23(4):461.
3. Simpson PV, Desai NM, Casari I, Massi M, Falasca M. Metal-based antitumor compounds: beyond cisplatin. Future Medicinal Chemistry. 2019;11(2):119-35.
4. Leonidova A, Pierroz V, Adams LA, Barlow N, Ferrari S, Graham B, et al. Enhanced cytotoxicity through conjugation of a “clickable” luminescent Re (I) complex to a cell-penetrating lipopeptide. ACS medicinal chemistry letters. 2014;5(7):809-14.
5. Regan M, O’Donnell E, Kelly W, Halabi S, Berry W, Urakami S, et al. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals of oncology. 2010;21(2):312-8.
6. Lazarević T, Rilak A, Bugarčić ŽD. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. European journal of
medicinal chemistry. 2017;142:8-31.

7. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology. 2014;740:364-78.

8. Philippe C, Didier D, Veena V. Design of Rhenium Compounds in Targeted Anticancer Therapeutics. Current Pharmaceutical Design. 2019;25(31):3306-22.

9. Konkankit CC, Marker SC, Knopf KM, Wilson JJ. Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. Dalton Transactions. 2018;47(30):9934-74.

10. Simpson PV, Falasca M, Massi M. Properties and prospects for rhenium(i) tricarbonyl N-heterocyclic carbene complexes. Chem Commun (Camb). 2018;54(88):12429-38.

11. Lo KK-W, Louie M-W, Sze K-S, Lau JS-Y. Rhenium (I) polypyridine biotin isothiocyanate complexes as the first luminescent biotinylation reagents: Synthesis, photophysical properties, biological labeling, cytotoxicity, and imaging studies. Inorganic chemistry. 2008;47(2):602-11.

12. Louie M-W, Liu H-W, Lam MH-C, Lau T-C, Lo KK-W. Novel luminescent tricarbonylrhenium (I) polypyridine tyramine-derived dipicolylammine complexes as sensors for zinc (II) and cadmium (II) ions. Organometallics. 2009;28(15):4297-307.

13. Choi AW-T, Louie M-W, Li SP-Y, Liu H-W, Chan BT-N, Lam TC-Y, et al. Emissive behavior, cytotoxic activity, cellular uptake, and PEGylation properties of new luminescent rhenium (I) polypyridine poly(ethylene glycol) complexes. Inorganic chemistry. 2012;51(24):13289-302.

14. Bauer EB, Haase AA, Reich RM, Crans DC, Kühn FE. Organometallic and coordination rhenium compounds and their potential in cancer therapy. Coordination Chemistry Reviews. 2019;393:79-117.

15. King AP, Marker SC, Swanda RV, Woods JJ, Qian S-B, Wilson JJ. A Rhenium Isonitrile Complex Induces Unfolded Protein Response-Mediated Apoptosis in Cancer Cells. Chemistry – A European Journal. 2019;25(39):9206-10.

16. Konkankit CC, Vaughn BA, MacMillan SN, Boros E, Wilson JJ. Combinatorial Synthesis to Identify a Potent, Necrosis-Inducing Rhenium Anticancer Agent. Inorganic Chemistry. 2019;58(6):3895-909.

17. He L, Pan Z-Y, Qin W-W, Li Y, Tan C-P, Mao Z-W. Impairment of the autophagy-related lysosomal degradation pathway by an anticancer rhenium(i) complex. Dalton Transactions. 2019;48(13):4398-404.

18. Chang C-M, Lan K-L, Huang W-S, Lee Y-J, Lee T-W, Chang C-H, et al. 188Re-liposome can induce mitochondrial autophagy and reverse drug resistance for ovarian cancer: from bench evidence to preliminary clinical proof-of-concept. International journal of molecular sciences. 2017;18(5):903.

19. Wang F-X, Liang J-H, Zhang H, Wang Z-H, Wan Q, Tan C-P, et al. Mitochondria-Accumulating Rhenium(I) Tricarbonyl Complexes Induce Cell Death via Irreversible Oxidative Stress and Glutathione Metabolism Disturbance. ACS Applied Materials & Interfaces. 2019;11(14):13123-33.

20. North AJ, Karas JA, Ma MT, Blower PJ, Ackermann U, White JM, et al. Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDFk. Inorg Chem. 2017;56(16):9725-41.
21. Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcia E, Chérel M, et al. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne). 2019;6:132.

22. Sharma R, Kumar C, Mallia MB, Kameswaran M, Sarma HD, Banerjee S, et al. In Vitro Evaluation of (188)Re-HEDP: A Mechanistic View of Bone Pain Palliations. Cancer Biother Radiopharm. 2017;32(5):184-91.

23. Lange R, ter Heine R, van Wieringen WN, Tromp AM, Paap M, Bloemendal HJ, et al. Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines. Cancer Biother Radiopharm. 2017;32(1):16-23.

24. Knopf KM, Murphy BL, MacMillan SN, Baskin JM, Barr MP, Boros E, et al. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. J Am Chem Soc. 2017;139(40):14302-14.

25. Simpson PV, Casari I, Paternoster S, Skelton BW, Falasca M, Massi M. Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation. Chemistry. 2017;23(27):6518-21.

26. Domenichini A, Edmands JS, Adamska A, Begicevic R-R, Paternoster S, Falasca M. Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. Advances in Biological Regulation. 2019;72:63-77.

27. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-83.

28. Nieddu V, Piredda R, Bexell D, Barton J, Anderson J, Sebire N, et al. Engineered human mesenchymal stem cells for neuroblastoma therapeutics. Oncol Rep. 2019;42(1):35-42.

29. Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, et al. The soft agar colony formation assay. J Vis Exp. 2014(92):e51998-e.

30. Heppner DE, Dustin CM, Liao C, Hristova M, Veith C, Little AC, et al. Direct cysteine sulfenylation drives activation of the Src kinase. Nat Commun. 2018;9(1):4522.

31. Fishman MC, Stainier DY, Breitbart RE, Westerfield M. Zebrash: genetic and embryological methods in a transparent vertebrate embryo. Methods Cell Biol. 1997;52:67-82.

32. Casari I, Domenichini A, Sestito S, Capone E, Sala G, Rapposelli S, et al. Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. Cancers. 2019;11(11):1695.

33. Bevan CD, Lloyd RS. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem. 2000;72(8):1781-7.

34. Lombardo F, Shalaeva MY, Tupper KA, Gao F. ElogDoct: A Tool for Lipophilicity Determination in Drug Discovery. 2. Basic and Neutral Compounds. Journal of Medicinal Chemistry. 2001;44(15):2490-7.
35. Simpson PV, Casari I, Paternoster S, Skelton BW, Falasca M, Massi M. Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation. Chemistry – A European Journal. 2017;23(27):6518-21.

36. Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences. 2014;111(45):E4869-E77.

37. Kemble DJ, Sun G. Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc Natl Acad Sci U S A. 2009;106(13):5070-5.

38. Horzmann KA, Portales AM, Batcho KG, Freeman JL. Developmental toxicity of trichloroethylene in zebrafish (Danio rerio). Environmental Science: Processes & Impacts. 2020;22(3):728-39.

39. Sarmah S, Marrs JA. Zebrafish as a vertebrate model system to evaluate effects of environmental toxicants on cardiac development and function. International journal of molecular sciences. 2016;17(12):2123.

40. Panzica-Kelly JM, Zhang CX, Danberry TL, Flood A, DeLan JW, Brannen KC, et al. Morphological score assignment guidelines for the dechorionated zebrafish teratogenicity assay. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):382-95.

41. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discovery. 2018:CD-18-0229.

42. Leerberg DM, Hopton RE, Draper BW. Fibroblast growth factor receptors function redundantly during zebrafish embryonic development. Genetics. 2019;212(4):1301-19.

43. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009;28(31):2796-805.

44. Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, et al. A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. Clin Cancer Res. 2016;22(13):3398-409.

45. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology. 2017;14(10):611-29.

46. Capper MS, Packman H, Rehkämper M. Rhenium-Based Complexes and in Vivo Testing: A Brief History. Chembiochem. 2020.

47. Collery P, Desmaele D, Vijaykumar V. Design of Rhenium Compounds in Targeted Anticancer Therapeutics. Curr Pharm Des. 2019;25(31):3306-22.

48. Konkankit CC, Marker SC, Knopf KM, Wilson JJ. Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium. Dalton Trans. 2018;47(30):9934-74.

49. Simpson PV, Desai NM, Casari I, Massi M, Falasca M. Metal-based antitumor compounds: beyond cisplatin. Future Med Chem. 2019;11(2):119-35.
50. Thisse B, Thisse C, Weston JA. Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev Dyn. 1995;203(3):377-91.

51. Tonou-Fujimori N, Takahashi M, Onodera H, Kikuta H, Koshida S, Takeda H, et al. Expression of the FGF receptor 2 gene (fgfr2) during embryogenesis in the zebrafish Danio rerio. Mech Dev. 2002;119 Suppl 1:S173-8.

52. Scholpp S, Groth C, Lohs C, Lardelli M, Brand M. Zebrafish fgfr1 is a member of the fgf8 synexpression group and is required for fgf8 signalling at the midbrain-hindbrain boundary. Dev Genes Evol. 2004;214(6):285-95.

53. Byrne DP, Shrestha S, Galler M, Cao M, Daly LA, Campbell AE, et al. Aurora A regulation by reversible cysteine oxidation reveals evolutionarily conserved redox control of Ser/Thr protein kinase activity. Sci Signal. 2020;13(639).

54. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase. Journal of Medicinal Chemistry. 2011;54(20):7066-83.

Tables

Due to technological limitations, the tables are only available as a download in the supplementary files.